Spero Therapeutics, Inc. (SPRO)
1.215
0.00 (0.00%)
USD |
NASDAQ |
Aug 24, 16:00
1.21
0.00 (0.00%)
After-Hours: 20:00
Spero Therapeutics Gross Profit Margin (Quarterly)
Gross Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | 0.00% |
| December 31, 2025 | 0.00% |
| September 30, 2025 | 0.00% |
| June 30, 2025 | 0.00% |
| March 31, 2025 | 0.00% |
| December 31, 2024 | 0.00% |
| September 30, 2024 | 0.00% |
| June 30, 2024 | 99.97% |
| March 31, 2024 | 0.00% |
| December 31, 2023 | 99.95% |
| September 30, 2023 | 99.54% |
| June 30, 2023 | 55.84% |
| March 31, 2023 | 52.84% |
| December 31, 2022 | 99.22% |
| September 30, 2022 | 55.18% |
| June 30, 2022 | 67.52% |
| March 31, 2022 | -65.99% |
| December 31, 2021 | 80.08% |
| Date | Value |
|---|---|
| September 30, 2021 | 0.00% |
| June 30, 2021 | 0.00% |
| March 31, 2021 | |
| December 31, 2020 | |
| September 30, 2020 | 0.00% |
| June 30, 2020 | 0.00% |
| March 31, 2020 | 0.00% |
| December 31, 2019 | 0.00% |
| September 30, 2019 | 0.00% |
| June 30, 2019 | 0.00% |
| March 31, 2019 | 0.00% |
| December 31, 2018 | 0.00% |
| September 30, 2018 | 0.00% |
| June 30, 2018 | 0.00% |
| March 31, 2018 | 0.00% |
| December 31, 2017 | 0.00% |
| September 30, 2017 | 0.00% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Inovio Pharmaceuticals, Inc. | -- |
| Fortress Biotech, Inc. | 61.50% |
| Kura Oncology, Inc. | 97.07% |
| Legend Biotech Corp. | 61.52% |
| ACADIA Pharmaceuticals, Inc. | 90.81% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | 17.13% |
| Return on Assets | 12.43% |
| Return on Invested Capital | 16.06% |
| Return on Net Operating Assets | 62.88% |